References
- Adams R J, Fuhlbrigge A L, Finkelstein J A, Weiss S T. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109: 636–642
- Bellanti J A, Wallerstedt D B. Allergic rhinitis update: epidemiology and natural history. Allergy Asthma Proc 2000; 21: 367–370
- Skoner D P. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001; 108: S2–S8, (suppl)
- HealthSTAR Communications. Inc, in partnership with Schulman, Ronca & Bucuvalas Inc. Allergies in America: a landmark survey of nasal allergy sufferers. Executive summary. Altana Pharma US, Florham Park, NJ 2006
- Arshad S H. Indoor allergen exposure in the development of allergy and asthma. Curr Allergy Asthma Rep 2003; 3: 115–120
- Casale T B, Dykewicz M S. Clinical implications of the allergic rhinitis-asthma link. Am J Med Sci 2004; 327: 127–138
- Nayak A S. The asthma and allergic rhinitis link. Allergy Asthma Proc 2003; 24: 395–402
- Weiner J M, Abramson M J, Puy R M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. Br Med J 1998; 317: 1624–1629
- Skoner D P, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90: 56–62
- US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Allergic rhinitis: clinical development programs for drug products. April, 2000, http://www.fda.gov/cder/guidance/2718dft.htm Available from. Accessed April 28, 2006
- Chapman K R, Patel P, D'Urzo A D, Alexander M, Mehra S, Oedekoven C, Engelstatter R, Boulet L P. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005; 60: 330–337
- Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 2005; 115: 940–945
- Langdon C G, Adler M, Mehra S, Alexander M, Drollmann A. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005; 99: 1275–1285
- Lipworth B J, Kaliner M A, La Force C F, Baker J W, Kaiser H B, Amin D, Kundu S, Williams J E, Engelstaetter R, Banerji D D. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005; 94: 465–472
- Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005; 128: 1104–1114
- Nave R, Wingertzahn M A, Brookman S, Kaida S, Matsunaga T. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J Clin Pharmacol 2006; 46: 461–467
- Schmidt B M, Timmer W, Georgens A C, Hilt M, Mattinger C, Wurst W, Hormann K, Wehling M. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J Clin Pharmacol 1999; 39: 1062–1069
- Ratner P H, Wingertzahn M A, Hall N, Darken P, Shah T. Effects of coadministration of intranasal ciclesonide (CIC) and beclomethasone dipropionate (BDP) on cortisol suppression [abstract]. J Allergy Clin Immunol 2006; 117: S259, (suppl) Abstract 1003
- World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects, www.wma.net/e/policy/b3.htm Available from. Accessed April 28, 2006
- Weinbrenner A, Hüneke D, Zschiesche M, Engel G, Timmer W, Steinijans V W, Bethke T, Wurst W, Drollmann A, Kaatz H J, Siegmund W. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87: 2160–2163
- Sheth K K, Cook C K, Philpot E E, Prillaman B A, Witham L A, Faris M A, Klein K C, Rickard K A. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc 2004; 25: 115–120
- Wilson A M, Lipworth B J. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 1999; 54: 20–26
- Clark D J, Grove A, Cargill R I, Lipworth B J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51: 262–266